Article Text

Download PDFPDF
Diagnostic tests for thyroid antibodies: A comparison of the precipitin and latex-fixation (Hyland TA ) tests
  1. J. R. Anderson,
  2. W. W. Buchanan,
  3. R. B. Goudie,
  4. K. G. Gray
  1. University Department of Pathology at the Western Infirmary, Glasgow
  2. University Department of Medicine at the Western Infirmary, Glasgow

    Abstract

    The clinical significance of thyroid antibodies is discussed and it is concluded that, of the antibody tests which have been extensively applied, the precipitin test is the most useful for diagnostic purposes. The recently introduced Hyland TA test is compared with the precipitin test. The TA test gives a rapid result and is slightly more sensitive, but it remains undecided whether a true positive result is always indicative of clinically important degrees of chronic thyroiditis. The TA test also gives occasional false positive results, not indicative of antibody to thyroglobulin. Furthermore, approximately 12% of precipitin-positive sera from patients with Hashimoto's disease give negative TA tests, and since these also have low titres, or are negative, in the tanned red cell haemagglutination test, the precipitin test is the only simple method of demonstrating the antibody concerned. In spite of these disadvantages, the TA test is regarded as a useful procedure, and there are advantages in using both the precipitin and TA tests together for routine diagnostic purposes. A modification is described whereby the TA test reagent may be used to titrate antibody to thyroglobulin.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • 1 The TA test is a rapid slide test for detecting antibody to thyroglobulin. This reagent is produced by Hyland Laboratories of Los Angeles.